Kestra Medical Technologies (NASDAQ:KMTS) Research Coverage Started at Piper Sandler

Piper Sandler assumed coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a report released on Monday, MarketBeat.com reports. The firm issued an overweight rating and a $27.00 target price on the stock.

A number of other analysts have also commented on the company. The Goldman Sachs Group initiated coverage on Kestra Medical Technologies in a research note on Monday. They set a “neutral” rating and a $24.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Kestra Medical Technologies in a research report on Monday. They issued a “buy” rating and a $28.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Kestra Medical Technologies Stock Performance

Shares of KMTS stock opened at $25.70 on Monday. Kestra Medical Technologies has a 1 year low of $20.00 and a 1 year high of $26.06.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.